Personalizing Cancer Therapy For Complex Molecular Blueprints: Insights From The I-PREDICT Trial – Life Sciences, Biotechnology & Nanotechnology

One of the persistent challenges in precision oncology is the
fact that most advanced cancers are complex and highly
individualized. A recent study published by Jason K. Sicklick, MD
and colleagues (J. Clinical Oncology) tackles and provides a
possible solution to this problem. Traditional precision medicine
approaches tend to match patients with a single drug aimed at a
single biomarker, often defined by tumor type. But reality shows
that a typical advanced cancer harbors multiple driver alterations,
frequently five or more, that do not align neatly with histology.
This genomic complexity, combined with differences between patients
in age, frailty, organ function, metabolism, gender, and race,
means that the one-size-fits-all approach to drug choice and dosing
often misses the mark, either by under-treating or by causing
unnecessary side effects. Compounding the problem is the historical
barrier that most combination therapies require phase I trials to
establish safe dosing, a process that may be too slow and
impractical for patients with life-threatening disease.

In response, Sicklick and his colleagues used I-PREDICT
(Investigation of Profile-Related Evidence Determining
Individualized Cancer Therapy; NCT02534675) to study an innovative N-of-1
design in which each patient’s treatment was matched to their
unique constellation of pathogenic tumor alterations, often with
novel drug combinations. The team used various advanced genetic
sequencing technologies on tumor tissue and circulating tumor DNA
to create a comprehensive molecular profile for each patient. These
profiles were reviewed by a multidisciplinary molecular tumor
board, which recommended the best possible drug combination for
that specific genomic profile. A key metric, the “matching
score”, quantified how well the administered regimen targeted
the patient’s known pathogenic alterations. Because many drug
regimens had no prior dosing data, physicians started at lower
doses and adjusted upward or downward within the same patient based
on tolerance, rather than using conventional interpatient dose
escalation models.

The study enrolled 210 evaluable patients with unresectable or
metastatic cancers from various tissue origins. The median number
of pathogenic alterations was five and treatment diversity
reflected this complexity. 157 different drug regimens were
administered, 103 of which had no established safety or recommended
dose at the time. Frequent monitoring during the early weeks
allowed for individualized dose titration. Interestingly, serious
toxicity rates were lower in first-in-human combinations than in
regimens with established dosing, likely due to conservative
starting doses.

The results showed that the better the molecular match, the
better the outcome. Patients with a matching score above 50 percent
had significantly higher disease control rates, longer
progression-free survival, and longer overall survival compared to
those with lower scores. In other words, the degree of matching of
drugs to tumor molecular alterations (reflected by the matching
score) was found to associate significantly, independently, and
linearly with disease control rates and longer progression-free
survival and overall survival.

This work matters because it shows a viable path forward for
truly personalized cancer care, moving beyond tumor type or single
biomarker models to address the full spectrum of actionable
alterations. It integrates patient-specific clinical factors into
dosing decisions and uses modern genomic tools to build treatment
from the molecular blueprint up. While the findings are
hypothesis-generating and require confirmation in randomized
controlled trials, they offer a blueprint for how oncology could
evolve toward routinely delivering the right drugs, at the right
doses, at the right time—for each patient.

The content of this article is intended to provide a general
guide to the subject matter. Specialist advice should be sought
about your specific circumstances.